paliperidone palmitate
Erzofri
Pharmaceutical company: Luye Pharma
NEW FORMULATION
Injection: 351 mg/2.25 mL
INDICATION & DOSAGE
Schizophrenia and schizoaffective disorder
Adults: Initially, paliperidone (Erzofri) 351 mg IM administered in the deltoid muscle on treatment day 1, followed by monthly maintenance dose of 117 mg administered in the deltoid or gluteal muscles. Adjust monthly doses based on tolerability and efficacy using available strengths. Maximum monthly dose is 234 mg. See the manufacturer's instructions for missed dosage schedules.
Adjust-a-dose: For creatinine clearance 50 to less than 80 mL/minute, give paliperidone (Erzofri) 234 mg IM on treatment day 1, followed by monthly injections of 78 mg IM. Maximum monthly dose is 156 mg. This drug isn't recommended in patients with creatinine clearance less than 50 mL/minute.
Released: October 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
maralixibat
Livmarli
Pharmaceutical company: Mirum Pharmaceuticals
NEW FORMULATION
Oral solution: 19 mg/mL
NEW INDICATION & DOSAGE
Cholestatic pruritus in patients with Alagille syndrome
Adults and children ages 3 months and older: Initially, 190 mcg/kg PO once daily, 30 minutes before a morning meal, using a 9.5-mg/mL solution. After 1 week, increase dosage to 380 mcg/kg once daily, as tolerated. Maximum dose, 28.5 mg (3 mL) daily in patients weighing 70 kg or more.
Cholestatic pruritus in patients with progressive familial intrahepatic cholestasis
Adults and children ages 12 months and older:Initially, 285 mcg/kg PO once daily in the morning using a 19-mg/mL solution. Increase dosage to 285 mcg/kg b.i.d., 428 mcg/kg b.i.d., and then to 570 mcg/kg b.i.d., as tolerated. Maximum daily dose, 38 mg (2 mL) in patients weighing 60 kg or more.
Released: October 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
epinephrine
Neffy
Pharmaceutical company: ARS Pharma
NEW FORMULATION
Nasal spray: 2 mg/0.1 mL per single-dose spray
NEW INDICATION & DOSAGE
Type I allergic reactions, including anaphylaxis
Adults and children weighing 30 kg or more: One spray (2 mg) into one nostril. If there is no clinical response or worsening symptoms, repeat the dose after 5 minutes in the same nostril.
Released: October 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
durvalumab
Imfinzi
Pharmaceutical company: AstraZeneca
NEW INDICATION & DOSAGE
Resectable non–small-cell lung cancer with no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase arrangements, in combination with platinum-containing chemotherapy before surgery, and then continued as a single agent after surgery
Adults weighing 30 kg or more: Before surgery, 1,500 mg IV every 3 weeks with chemotherapy for up to 4 cycles; after surgery, 1,500 mg as a single agent every 4 weeks for up to 12 cycles or until the disease progresses or unacceptable toxicity occurs.
Adults weighing less than 30 kg:Before surgery, 20 mg/kg IV every 3 weeks with chemotherapy for up to 4 cycles; after surgery, 20 mg/kg IV as a single agent every 4 weeks for up to 12 cycles or until the disease progresses or unacceptable toxicity occurs.
Released: October 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer